ConductScience.org, home

Library / Trial comparisons

Fluarix Tetra vs mRNA-1010: Number of Participants With First Episode of RT-PCR Confirmed Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Strain of Influenza Virus

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.007390.004880.0112wilsonClinicalTrials.gov
Risk in group 20.008050.005420.012wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.000669-0.00530.00393newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9170.5151.63logClinicalTrials.gov
Odds ratio, group 1 over group 20.9160.5131.64logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Fluarix Tetra than on mRNA-10101,500from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Fluarix TetraParticipants received a single dose of Fluarix Tetra by IM injection on Day 1.222,979OG000ClinicalTrials.gov
Group 2mRNA-1010Participants received a single dose of mRNA-1010 by IM injection on Day 1.242,980OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Participants With First Episode of RT-PCR Confirmed Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Strain of Influenza VirusClinicalTrials.gov
DescriptionA CDC-defined ILI was defined as body temperature ≥37.8°C (100°F) accompanied by cough and/or sore throat.ClinicalTrials.gov
Time frame14 days post-vaccination through Day 181 (Month 6)ClinicalTrials.gov
Population
The mITT Set included all participants who were randomized and received any study vaccination and who provided any follow-up for ILI beginning at least 14 days following administration of study intervention.
ClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsClinicalTrials.gov
NCT numberNCT05415462ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsSeasonal InfluenzaClinicalTrials.gov
InterventionsmRNA-1010, Fluarix TetraClinicalTrials.gov
Lead sponsorModernaTX, Inc.ClinicalTrials.gov
Results first posted2024-09-24ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT05415462?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.